Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cullin-RING ligase 4-Cereblon (CRL4-CRBN) E3 ubiquitin ligase complex is a multi-protein assembly that plays a critical role in targeted protein degradation via the ubiquitin-proteasome system. The complex is composed of the scaffold protein Cullin-4 (CUL4A or CUL4B), Ring-Box 1 (RBX1/ROC1), DNA damage-binding protein 1 (DDB1), and the substrate recognition receptor Cereblon (CRBN). Under physiological conditions, the complex regulates cellular homeostasis, cell cycle progression, and embryonic development by tagging specific native substrates with ubiquitin for proteasomal degradation.
The CRL4-CRBN complex is a highly validated therapeutic target, particularly in hematological malignancies such as multiple myeloma and myelodysplastic syndromes. Immunomodulatory imide drugs (IMiDs) like thalidomide, lenalidomide, and pomalidomide, as well as next-generation cereblon E3 ligase modulators (CELMoDs), bind directly to the tri-tryptophan pocket of CRBN. This binding alters the substrate specificity of the complex, redirecting it to recruit and degrade non-physiological 'neosubstrates' such as the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for myeloma cell survival. Furthermore, the CRL4-CRBN complex is widely exploited in targeted protein degradation (TPD) drug discovery, where proteolysis-targeting chimeras (PROTACs) hijack the complex to selectively degrade typically undruggable disease-causing proteins.
Small-molecule modulators (IMiDs and CELMoDs) bind to the cereblon (CRBN) subunit of the CRL4-CRBN complex, altering its surface topography and substrate specificity to recruit and ubiquitinate non-native 'neosubstrate' proteins (e.g., IKZF1, IKZF3, SALL4, GSPT1) for proteasomal degradation. Additionally, proteolysis-targeting chimeras (PROTACs) utilize the complex to induce proximity-driven ubiquitination and degradation of specific proteins of interest.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cullin-RING ligase 4-Cereblon E3 ubiquitin ligase complex (CRL4-CRBN).